StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib) by Quarter

RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib): $320M in Q3 2026, up 61.6% from a year earlier. That is the highest of the 11 quarters on record here.

Latest, Q3 2026
320
Period ended Sep 30, 2026
Change on a year earlier
+61.6%
198 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-10-21) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide sales ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026320+61.6%Form 10-Q (filed 2026-10-21) ↗
Q2 2026Jun 28, 2026289+61.5%Form 10-Q (filed 2026-07-23) ↗
Q1 2026Mar 29, 2026257+82.3%Form 10-Q (filed 2026-04-22) ↗
Q4 2025Dec 28, 2025216+77.0%Form 10-K (filed 2026-02-11) ↗
Q3 2025Sep 28, 2025198+122.5%Form 10-Q (filed 2026-10-21) ↗
Q2 2025Jun 29, 2025179+159.4%Form 10-Q (filed 2026-07-23) ↗
Q1 2025Mar 30, 2025141+200.0%Form 10-Q (filed 2026-04-22) ↗
Q4 2024Dec 29, 2024122–Form 10-K (filed 2026-02-11) ↗
Q3 2024Sep 29, 202489–Form 10-Q (filed 2025-10-22) ↗
Q2 2024Jun 30, 202469–Form 10-Q (filed 2025-07-24) ↗
Q1 2024Mar 31, 202447–Form 10-Q (filed 2025-04-23) ↗

Breakdown

What makes up RYBREVANT / LAZCLUZE (amivantamab / lazertinib)

Cite this data

StockData. (2026). Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib) ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-rybrevant

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.